CCCC C4 Therapeutics
- 6.230
- +0.060+0.97%
C4 Therapeutics News
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation scienc
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation scienc
Here's Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)
C4 Therapeutics Initiates Stock Option Repricing for Retention
Over $700 million! Merck joins hands with C4T (CCCC.US) to develop anti-cancer proteolytic therapy
On March 4, C4 Therapeutics (CCCC.US) announced a licensing and cooperation agreement with Merck of Germany
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024
CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain MetastasisWATERTOWN, Mas
Express News | C4 Therapeutics Shares Are Trading Higher After the Company Announced a Strategic Discovery Collaboration With Merck KGaA Against Critical Oncogenic Proteins, in Which the Company Will Receive a $16 Million Upfront Payment
C4 Therapeutics Strikes Major Oncology Deal With Merck KGaA
Express News | C4 Therapeutics Has Entered Into A License Agreement With Merck KGaA, To Exclusively Discover Two Targeted Protein Degraders Against Critical Oncogenic Proteins, C4 Therapeutics Will Receive $16M As Upfront And Is Eligible Of Up $740M In Milestone Payment
C4 Therapeutics Announces Strategic Discovery Research Collaboration With Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
Collaboration Focused on Two Targeted Protein Degraders from C4T's Internal Discovery PipelineC4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery Research
Analysts Just Made A Noticeable Upgrade To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Forecasts
C4 Therapeutics, Inc. (NASDAQ:CCCC) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts.
Express News | Morgan Stanley Maintains Equal-Weight on C4 Therapeutics, Raises Price Target to $8
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Halozyme (HALO) and Eli Lilly & Co (LLY)
C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates
Shareholders of C4 Therapeutics, Inc. (NASDAQ:CCCC) will be pleased this week, given that the stock price is up 13% to US$8.99 following its latest yearly results. Despite revenues of US$21m fal
C4 Therapeutics Full Year 2023 Earnings: Misses Expectations
C4 Therapeutics Price Target Raised to $13.00/Share From $12.00 by Stifel
C4 Therapeutics Price Target Raised to $13.00/Share From $12.00 by Stifel
Strong Financials and Promising Drug Pipeline Bolster Buy Rating for C4 Therapeutics
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Insulet (PODD) and Healthequity (HQY)
Options Corner: Stocks with Notable Option Volatility Include CGC, CCCC and PCT
Welcome to our column, where we track and analyze the ever-changing volatility of the S&P 500 and NASDAQ indices and stocks with notable option volatility.
Stifel Nicolaus Sticks to Its Buy Rating for C4 Therapeutics (CCCC)
Analysis
Price Target
No Data
